Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | PHASE1 | RECRUITING | 574 | — | — | Jan 8, 2026 | Oct 1, 2028 | Jun 1, 2026 | 5 | United States |
Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5
Number of patients with changes from baseline in vital signs
Number of patients with changes from baseline in ECG test values
Number of patients with changes from baseline in clinical laboratory test values
Number of patients with dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| Arm A: RMC-5127 Monotherapy | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Arm B: RMC-5127 + Daraxonrasib Combination | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Arm C: RMC-5127 + Cetuximab Combination | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| RMC-5127 | DRUG | oral tablets |
| daraxonrasib | DRUG | oral tablets |
| cetuximab | DRUG | IV infusion |
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy. * Received and progressed or been intolerant...